MNTA News and Press, Momenta Pharmaceuticals Inc. From 03/26/20

Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...

Healthcare Pulse A new reality dawned as the stock market entered a bear market. It wasn't a tiptoe moment for the bear. The market simply plummeted into a bear market canyon. Just from March 4 to March 12, in about a week, the S&P 500 and Nasdaq declined 20% or more. The healthcare ...

Drug stocks soared on Friday with the overall stock market rebounding from Thursday's historic sell-off. Several also spiked near the end of the day today as President Trump held a news conference where he declared a national emergency that he said would "open up access" to up to $50 billion to ...

Allakos (NASDAQ: ALLK ) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko. More news on: Allakos Inc., Avadel Pharmaceuticals plc, Krystal Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

Image source: The Motley Fool. Momenta Pharmaceuticals Inc   (NASDAQ: MNTA) Q4 2019 Earnings Call Feb 26, 2020 , 8:30 a.m. ET Operator Continue reading

Momenta Pharmaceuticals, Inc. (MNTA) Q4 2019 Earnings Conference Call February 26, 2020 8:30 AM ET Company Participants Patty Eisenhaur - Vice President of Investor Relations & Communications Craig Wheeler - President & Chief Executive Officer Young Kwon - Chief Financial...

The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Momenta Pharmaceuticals (NASDAQ: MNTA ): Q4 GAAP EPS of -$0.85 misses by $0.28 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 -- -- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line ...